Amedica to Present at the 13th Annual Needham Healthcare Conference

SALT LAKE CITY, April 4, 2014 (GLOBE NEWSWIRE) -- Amedica (Nasdaq:AMDA) announced today that it has been invited to present at the 13th Annual Needham Healthcare Conference, being held at the Westin Grand Central Hotel on April 8th and 9th in New York City.

Amedica's CEO and President, Eric Olson, is scheduled to present at 8:40am on April 8, 2014. The Company will join approximately 120 prominent companies in the biomaterials, medical devices, biotechnology, specialty pharmaceutical, medical technology and diagnostic sectors. The presenters will include a selection of leading public and private companies. Needham's Healthcare Conference focuses on connecting emerging life science companies and investors.

About Amedica Corporation

Amedica is a commercial biomaterials company focused on using its Silicon Nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica markets spinal fusion products and is developing product candidates for use in total hip and knee joint replacements. Amedica operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and currently marketed in the U.S. and select markets in Europe and South America.

The Company's news releases and other information for investors are located at www.amedica.com.

Forward-Looking Statements

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company's expectations or beliefs concerning future events of the company's financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company's dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company's products, compliance costs and the effects of government regulation. Actual results may differ materially from expected results included in these statements.

CONTACT: Amedica Investor Relations,
         Bill Hockett, Alden Communications
         (801) 947-6264
         amedica@aldencommunications.com

Released April 4, 2014